Pfizer has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, New York research site.
A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.
A Canadian drug distributor began recalling a small quantity of Pfizer birth control pills this week after it accidentally shipped out expired product. Pfizer credited the company with quick action, but it is the kind of issue that in the past has led to litigation against drugmakers over unwanted pregnancies.
When Pfizer teamed up with Merck KGaA on lung cancer, the headlines zeroed in on the sexiest part of the $2.85 billion deal: their immuno-oncology plans. The two companies will work together on cancer-fighters in the PD-L1 arena, one of the hottest fields in pharma these days, including a Phase II Merck drug.
When Pfizer announced its $15 billion deal to buy sterile injectable specialist Hospira, execs said they had studied FDA concerns over Hospira manufacturing before pulling the trigger. But Hospira just keeps giving Pfizer new lessons. Today, the FDA posted a warning letter it recently sent to Hospira CEO F. Michael Ball for a plant in Italy.
Got severe food allergies, Montreal Canadiens fans? Worry not: Thanks to Pfizer, anaphylaxis med EpiPen is near.
As it beefs up its vaccines business, Pfizer's looking to bolster revenue from the top-selling Prevenar family of shots. But on that front, it's come up against a roadblock in China--and so it's shutting down its vaccines marketing there.
Pfizer said on Thursday that it would be pulling its vaccines sales business out of China after the import license of Prevenar, its top-selling treatment, was not renewed, Reuters reported.
Pfizer Inc. has halted vaccine operations in China following failure to get a license renewal for its existing Prevenar shot and as a new wider coverage of the same vaccine for pneumococcal diseases also awaits approval, highlighting issues with the approval process in the Middle Kingdom as well as fierce competition in the vaccines space regionally.
Australia's reimbursement agency has lagged developed country counterparts in paying for newly approved new cancer therapies, highlighting problems at the tail end of a system that patients and industry complain is broken.